J Am Coll Cardiol. 2018;72:255 67. 4.3. Interruption and Bridging Anticoagulation S4.3-1. Douketis JD, Spyropoulos AC, Kaatz S, et al. Perioperative bridg- ing anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015;373:823 33. S4.3-2. Pollack CV Jr, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal - full cohort analysis. N Engl J Med. 2017;377:431 41. S4.3-3. Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373:2413 24. S4.3-4. Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131 41. 4.4.1. Percutaneous Approaches to Occlude the Left Atrial Appendage S4.4.1-1. Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA. 2014;312:1988 98. S4.4.1-2. Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evalu- ation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014;64:1 12. S4.4.1-3. Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke Prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65:2614 23. S4.4.1-4. Reddy VY, Gibson DN, Kar S, et al. Post-approval US experience with left atrial appendage closure for stroke prevention in atrial fibrilla- tion. J Am Coll Cardiol. 2017;69:253 61. S4.4.1-5. Boersma LVA, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri- procedural outcomes from the EWOLUTION registry. Eur Heart J. 2016;37:2465 74. S4.4.1-6. Reddy VY, M bius-Winkler S, Miller MA, et al. 